Truffle Capital Congratulates VEXIM on its Acquisition by Stryker Corporation

November 3, 2017

Truffle Capital, a leading European venture capital firm committed to supporting the creation and development of innovative start-ups, is proud to announce the ongoing acquisition of Vexim, a leader inmini-invasive spine surgery, by Stryker Corporation for an amount (on a fully diluted basis) of 183 million Euros (20 € per share). For details of the acquisition, please refer exclusively to Vexim and Stryker press releases.

Truffle Capital, which co-founded Vexim in 2006 and has remained the company's lead investor ever since, has been involved in all of Vexim's structuring, management team building, R&D, development and commercial stages. Winner of the NYSE Euronext's best IPO award of 2012 (Euronext Growth: ALVXM), Vexim has successfully marketed its products in Europe, and is currently preparing, with an international clinical trial and subject to FDA clearance, the potential market launch of its SpineJack® product in the United States in 2018. Vexim will now join Stryker's"Interventional Spine" division.

According to Dr. Philippe Pouletty, Co-Founder and Managing Director of Truffle Capital, "Vexim's success story and its acquisition by Stryker highlight the dynamism of radical innovation in the French MedTech sector, along with the entrepreneur-investor role played by Truffle Capital."

Truffle Capital congratulates Vincent Gardès, CEO of Vexim, and his entire team, and thanks the company's co-investors, including Kreaxi and Bpifrance. Also co-founded by Truffle, Symetis, which specializes in transcatheter aortic valves, was acquired in early 2017 by Boston Scientific. An active investor in the MedTech field, Truffle Capital is also a co-founder and shareholder of the following companies: in the cardiovascular field, Carmat (total artificial heart), Epygon (transcatheter mitral valve), Kephalios (adjustable mitral ring), Kardiosis (endoprosthesis for aortic aneurysm); in urology, Myopowers (artificial urinary sphincter); and in interventional high intensity ultrasounds, Theraclion. The firm also supports lead investments in biotech companies, including Abivax and Pharnext.

For more information, please visit www.truffle.fr

 
See the latest posts on our homepage


Share

Topic Area: Press Release


Recent Posts
Recent Posts

Los Angeles hospital closes due to earthquake standards


Pacific Alliance Medical Center would have had to invest $100 million in its 150-year-old building to come into compliance with California's seismic standards

12/15/2017

Adding beds might not solve Canadian 'hallway medicine'


Some say healthcare crunch needs more staff and innovation

12/15/2017

Hawaii State Hospital requires security upgrades before renovations


Oahu puts new demands on the hospital before it can expand

12/15/2017

Hospitals save lives and money by investing in climate resilience


New report says preparing for extreme weather offers significant financial benefit

12/15/2017

Focus: Lighting

Your healthcare facility's LED retrofit checklist


How do you begin to coordinate and come up with funds to replace lighting systems across thousands of square feet?

12/15/2017





Post Comment




FREE
NEWSLETTER

• News and Updates
• Webcast Alerts
• Building Technologies



All fields are required.